Merck & Co., Inc. (MRK)
| Market Cap | 248.03B |
| Revenue (ttm) | 63.17B |
| Net Income (ttm) | 12.15B |
| Shares Out | 2.53B |
| EPS (ttm) | 4.78 |
| PE Ratio | 20.51 |
| Forward PE | 10.89 |
| Dividend | $3.24 (3.30%) |
| Ex-Dividend Date | Dec 16, 2024 |
| Volume | 10,830,057 |
| Open | 98.83 |
| Previous Close | 99.52 |
| Day's Range | 97.90 - 99.67 |
| 52-Week Range | 94.48 - 134.63 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 129.07 (+31.64%) |
| Earnings Date | Feb 4, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $129.07, which is an increase of 31.64% from the latest price.
News
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel invest...
Stock Of The Day: Where Does The Merck Downtrend End?
Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend.
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines, with strong revenue from Keytruda and Gardasil despite challenges in China. Strategic acquisitions and partn...
Merck's HIV treatment meets main goal of two late-stage studies
Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies.
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Topline Results from Phase 3 Trials Evaluating Once-Daily, Oral Doravirine/Islatravir for the Treatment of Adults with HIV-1 Infection.
Merck's weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral) de...
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk's dominance in the weight-loss market.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million upfront...
Merck signs up to $2 bln obesity drug deal with Chinese biotech Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug.
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered i...
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts BLA for Clesrovimab, Merck's Investigational Long-Acting MAb Designed to Protect Infants from RSV During their First RSV Season.
Merck: Buy Opportunity Backed By Growth
Merck: Buy Opportunity Backed By Growth
Merck discontinues development of 2 cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibos...
Merck's KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the Nati...
Merck Has Become Very Cheap Again
Merck's shares have declined, making its dividend yield climb and valuation compress, presenting an attractive investment opportunity at current prices. Keytruda, the company's largest drug, continues...
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG CHMP Opinion for VHL & RCC.
14 Upcoming Dividend Increases
I focus on companies consistently increasing dividends and beating benchmarks, using data from the U.S. Dividend Champions spreadsheet and NASDAQ. The list includes companies with at least five years ...
2 Ideal Buys From 50 'Safer' Dividends In 100 December Sustainables
Calvert Research and Management ranked the 1,000 largest publicly traded companies by ESG performance, identifying the top 100 sustainable companies for 2024. Among 78 dividend paying sustainable comp...
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
RAHWAY, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LY...
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer.
Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial...
Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)
Merck & Co. Inc. (NYSE:MRK) Citi's 2024 Global Healthcare Conference December 5, 2024 8:00 AM ET Company Participants Rob Davis - Chairman and CEO Eliav Barr - Senior VP, Head of Global Clinical Deve...